Published in Biol Chem on April 01, 2010
Proteomic analyses reveal an acidic prime side specificity for the astacin metalloprotease family reflected by physiological substrates. Mol Cell Proteomics (2011) 1.20
The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10. Cell Mol Life Sci (2012) 1.05
The metalloproteases meprin α and meprin β: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis. Biochem J (2013) 1.04
Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol (2012) 1.02
Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. J Biol Chem (2011) 1.01
Meprin A metalloproteinase and its role in acute kidney injury. Am J Physiol Renal Physiol (2013) 0.99
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie (2010) 0.97
Structural basis for the sheddase function of human meprin β metalloproteinase at the plasma membrane. Proc Natl Acad Sci U S A (2012) 0.94
Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem (2010) 0.91
Enhanced activity of meprin-α, a pro-migratory and pro-angiogenic protease, in colorectal cancer. PLoS One (2011) 0.87
Role of meprins to protect ileal mucosa of Crohn's disease patients from colonization by adherent-invasive E. coli. PLoS One (2011) 0.86
Protease-armed bacteria in the skin. Cell Tissue Res (2012) 0.84
Meprinα transactivates the epidermal growth factor receptor (EGFR) via ligand shedding, thereby enhancing colorectal cancer cell proliferation and migration. J Biol Chem (2012) 0.83
Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clin Exp Metastasis (2013) 0.78
Putative functions of tissue kallikrein-related peptidases in vaginal fluid. Nat Rev Urol (2016) 0.75
The Metalloprotease Meprin β Is an Alternative β-Secretase of APP. Front Mol Neurosci (2017) 0.75
Toward an integrative analysis of the tumor microenvironment in ovarian epithelial carcinoma. Cancer Microenviron (2011) 0.75
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol (2011) 4.50
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet (2004) 2.53
Assessment of unspecific near-infrared dyes in laser-induced fluorescence imaging of experimental arthritis. Acad Radiol (2006) 1.80
Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet (2006) 1.51
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem (2006) 1.31
The alpha and beta subunits of the metalloprotease meprin are expressed in separate layers of human epidermis, revealing different functions in keratinocyte proliferation and differentiation. J Invest Dermatol (2007) 1.23
Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol (2004) 1.18
Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging (2011) 1.18
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost (2004) 1.17
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem (2006) 1.13
Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res (2013) 1.13
Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J Proteome Res (2011) 1.12
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer (2005) 1.10
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat (2007) 1.08
Processing of procollagen III by meprins: new players in extracellular matrix assembly? J Invest Dermatol (2010) 1.07
The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10. Cell Mol Life Sci (2012) 1.05
The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. J Biol Chem (2012) 1.05
Sensory neuropathy and signs of central sensitization in patients with peripheral arterial disease. Pain (2006) 1.04
Working memory and lexical ambiguity resolution as revealed by ERPs: a difficult case for activation theories. J Cogn Neurosci (2003) 1.04
The metalloproteases meprin α and meprin β: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis. Biochem J (2013) 1.04
Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. J Biol Chem (2011) 1.01
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost (2005) 1.01
The morphosyntactic decomposition and semantic composition of German compound words investigated by ERPs. Brain Lang (2006) 0.99
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem (2008) 0.99
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn (2010) 0.98
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie (2010) 0.97
Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site. J Mol Biol (2006) 0.96
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am J Pathol (2010) 0.96
Let it flow: Morpholino knockdown in zebrafish embryos reveals a pro-angiogenic effect of the metalloprotease meprin alpha2. PLoS One (2010) 0.94
Structural basis for the sheddase function of human meprin β metalloproteinase at the plasma membrane. Proc Natl Acad Sci U S A (2012) 0.94
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat (2007) 0.94
Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem (2003) 0.94
LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries. J Proteome Res (2014) 0.94
Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb Haemost (2003) 0.93
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des (2003) 0.93
Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol (2004) 0.93
Metalloproteases meprin α and meprin β are C- and N-procollagen proteinases important for collagen assembly and tensile strength. Proc Natl Acad Sci U S A (2013) 0.92
High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett (2002) 0.92
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn (2010) 0.92
Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem (2012) 0.92
Image quality of noninvasive coronary angiography using multislice spiral computed tomography and electron-beam computed tomography: intraindividual comparison in an animal model. Invest Radiol (2004) 0.92
Fetuin-A and cystatin C are endogenous inhibitors of human meprin metalloproteases. Biochemistry (2010) 0.90
The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Biochem J (2008) 0.90
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol Chem (2006) 0.89
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Med (2008) 0.89
Comparison of the iron oxide-based blood-pool contrast medium VSOP-C184 with gadopentetate dimeglumine for first-pass magnetic resonance angiography of the aorta and renal arteries in pigs. Invest Radiol (2004) 0.89
Metalloprotease meprin beta in rat kidney: glomerular localization and differential expression in glomerulonephritis. PLoS One (2008) 0.88
Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer. Biol Chem (2010) 0.88
Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells. Mol Cancer (2012) 0.88
Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol (2015) 0.87
Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma. Histopathology (2010) 0.87
Structural basis of the zinc inhibition of human tissue kallikrein 5. J Mol Biol (2007) 0.87
Coronary MR angiography: experimental results with a monomer-stabilized blood pool contrast medium. Radiology (2002) 0.87
Two alpha subunits and one beta subunit of meprin zinc-endopeptidases are differentially expressed in the zebrafish Danio rerio. Biol Chem (2007) 0.87
Enhanced activity of meprin-α, a pro-migratory and pro-angiogenic protease, in colorectal cancer. PLoS One (2011) 0.87
Rapid binding of electrostatically stabilized iron oxide nanoparticles to THP-1 monocytic cells via interaction with glycosaminoglycans. Basic Res Cardiol (2013) 0.86
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat (2010) 0.86
Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading. Matrix Biol (2009) 0.86
Role of meprins to protect ileal mucosa of Crohn's disease patients from colonization by adherent-invasive E. coli. PLoS One (2011) 0.86
Whole-heart coronary magnetic resonance angiography: contrast-enhanced high-resolution, time-resolved 3D imaging. Invest Radiol (2007) 0.86
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J Med Chem (2002) 0.86
A vascular stent as an active component for locally enhanced magnetic resonance imaging: initial in vivo imaging results after catheter-guided placement in rabbits. Invest Radiol (2003) 0.85
Morpholino knockdown of the ubiquitously expressed transmembrane serine protease TMPRSS4a in zebrafish embryos exhibits severe defects in organogenesis and cell adhesion. Biol Chem (2011) 0.85
A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15. Biol Chem (2009) 0.85
A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36. Endocrinology (2011) 0.85
Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7. Proc Natl Acad Sci U S A (2007) 0.84
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. Biol Chem (2003) 0.84
Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. Biol Chem (2014) 0.84
Meprinα transactivates the epidermal growth factor receptor (EGFR) via ligand shedding, thereby enhancing colorectal cancer cell proliferation and migration. J Biol Chem (2012) 0.83
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. Biol Chem (2006) 0.83
A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread. Biomaterials (2013) 0.83
Iron oxide magnetic nanoparticles highlight early involvement of the choroid plexus in central nervous system inflammation. ASN Neuro (2013) 0.83
Transglutaminase-1 and bathing suit ichthyosis: molecular analysis of gene/environment interactions. J Invest Dermatol (2009) 0.83
Coronary artery disease: new insights and their implications for radiology. Eur Radiol (2003) 0.82
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects. Breast Care (Basel) (2008) 0.82
Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer. PLoS One (2013) 0.82
Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa. Biochem J (2010) 0.82
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers. Crit Rev Clin Lab Sci (2014) 0.82
Short-term TNFα shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17. Biochim Biophys Acta (2013) 0.82
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin. Eur J Biochem (2002) 0.82
Interdependence of kallikrein-related peptidases in proteolytic networks. Biol Chem (2010) 0.82
Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer. Clin Chem (2006) 0.81
A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding. Clin Biochem (2011) 0.81
Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. Biol Chem (2014) 0.81
Pyoderma gangrenosum of the vaginal vault after vaginal hysterectomy: only the correct diagnosis of a rare entity can prevent long-term morbidity. Arch Gynecol Obstet (2013) 0.81
TMPRSS4 is a type II transmembrane serine protease involved in cancer and viral infections. Biol Chem (2012) 0.81
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction. Recent Results Cancer Res (2003) 0.81
Soluble tissue actor interferes with angiostatin-mediated inhibition of endothelial cell proliferation by lysine-specific interaction with plasminogen kringle domains. Thromb Haemost (2002) 0.80
Focal liver lesions: SPIO-, gadolinium-, and ferucarbotran-enhanced dynamic T1-weighted and delayed T2-weighted MR imaging in rabbits. Radiology (2006) 0.80
Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecol Oncol (2012) 0.80
Preclinical characterization of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as a blood pool contrast medium for MR angiography. Acad Radiol (2002) 0.80
Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems. Biol Chem (2003) 0.80
Meprins process matrix metalloproteinase-9 (MMP-9)/gelatinase B and enhance the activation kinetics by MMP-3. FEBS Lett (2012) 0.80